Skip to content

Use of CADISS Medical Device to Facilitate Dissection of Epidural Fibrosis in Revision Spine Surgery

Use of CADISS Medical Device to Facilitate Dissection of Epidural Fibrosis in Patients Who Undergo Revision in Spine Surgery After at Least One Year (CADISS1701)

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05016739
Enrollment
21
Registered
2021-08-23
Start date
2018-10-22
Completion date
2020-11-30
Last updated
2021-08-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Spine Surgery

Keywords

spine, lumbar, surgery, revision, CADISS, fibrosis, chemically assisted dissection

Brief summary

The CADISS® System, Chemically Assisted mechanical DISSection, is intended for the selective detachment of pathological tissue layers and/or fibrotic tissues in various surgical procedures without using cutting instruments. It is based on the property of the drug mesna (Sodium 2-mercaptoethane sulfonate) to cleave the disulfide bonds responsible for the adherence of pathological tissues and for the strength of fibrosis. Revision spine surgery is more difficult than primary surgery because of the development of fibrosis and scar tissues since the first operation. Fibrosis may develop in the spinal canal and will adhere strongly to the dura mater and to the nerve roots. This study is a prospective, multi-sites, open label, single cohort clinical trial evaluating the use of CADISS medical devices to facilitate dissection of epidural fibrosis in patients who undergo a revision in spine surgery after at least one year.

Interventions

DEVICECADISS

The CADISS® device was procured from AuXin Surgery. It consists in three elements: 1. A single use disposable Remote Kit, containing a sterile cartridge, which prepares the Drug Product immediately before use, and the sterile tubing for fluid connexion. The Drug Product is a 30 ml sterile 5% mesna solution of pH 7.3+/-0.5 2. Reusable stainless steel non-cutting mechanical instruments similar to those used in the normal practice, except for the provision of an internal irrigation channel bringing the Drug Product at the working edge. 3. A pedal controlled electric motor driving the peristaltic cassette included in the disposable tubing in order to control the dispensing of the Drug Product during the procedure.

Sponsors

AuXin Surgery SA
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* ≥ 18 years old, weight \> 30 Kg * Eligible for Spine revision surgery, at least one year after primary surgery * Agree to participate and sign the informed consent The age and weight of patient are defined according to the instruction for use of the CADISS System currently on the EU market.

Exclusion criteria

* \< 18 years old * Weight ≤ 30 kg * Primary surgery * Known hypersensibility to mesna * Patient is pregnant, breastfeeding or has wish of pregnancy during the study. * Unable to sign the informed consent * Participation in any study involving an investigational drug or device within the past 3 Months. * Individuals under tutorship or trusteeship.

Design outcomes

Primary

MeasureTime frameDescription
Ability of the CADISS® System to dissect fibrosis without cuttingSurgeryPercentage of successful dissection

Secondary

MeasureTime frameDescription
The facilitation of fibrosis detachment with the CADISS SystemSurgeryLikert scale - 0 to 10, the parameter is evaluated in comparison to the current surgeon practice. A score of 5 representing an appreciation of equivalence for the parameter with the current practice
The reduction of bleeding with the use of the CADISS SystemSurgeryLikert scale - 0 to 10, the parameter is evaluated in comparison to the current surgeon practice. A score of 5 representing an appreciation of equivalence for the parameter with the current practice
The capability of the CADISS system to highlights cleavage planeSurgeryLikert scale - 0 to 10, the parameter is evaluated in comparison to the current surgeon practice. A score of 5 representing an appreciation of equivalence for the parameter with the current practice
Global satisfaction score when using theSurgeryLikert scale - 0 to 10, the parameter is evaluated in comparison to the current surgeon practice. A score of 5 representing an appreciation of equivalence for the parameter with the current practice
The ease of use of the CADISS SystemSurgeryLikert scale - 0 to 10. A score of 0 representing the worse outcome
The easy of control of the topical application with the CADISS SystemSurgeryLikert scale - 0 to 10. A score of 0 representing the worse outcome
Adverse eventssurgery, at hospital discharge minimum 1 day after surgery, 6 weeksAll CADISS related Adverse events will be reported
The speed of action of the mesna solution after local instillationSurgeryLikert scale - 0 to 10. A score of 0 representing the worse outcome

Countries

Belgium

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026